MedPath

Efficacy of Mizoribine (MZR) treatment for gastrointestinal symptoms in kidney transplant recipients using mycophenolate mofetil (MMF). - Open-label, multicenter, randomized, controlled trial –

Not Applicable
Conditions
Kidney transplantation
Registration Number
JPRN-UMIN000008649
Lead Sponsor
Tokyo Women Medical University, Dep. Urology
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
200
Inclusion Criteria

Not provided

Exclusion Criteria

1.currently undergoing acute rejection 2.positive for DSA 3.serum creatinine level of less than 3mg/dL 4.a severe infection other than viral infection 5.white blood cell counts of less than 3,000/mm3 6.pregnant women and women suspected of being pregnant 7.aged 19 or younger 8.considered inappropriate by the doctor

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Difference of GSRS results between the 1st day and a month later.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath